Lineage Cell Therapeutics
LCTX
58 hedge funds and large institutions have $60.9M invested in Lineage Cell Therapeutics in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 8 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 56 → 58 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $63.9M → $60.9M (-$3.03M)
4.79% less ownership
Funds ownership: 35.98% → 31.19% (-4.8%)
92% less call options, than puts
Call options by funds: $32K | Put options by funds: $407K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$1.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$771K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$462K |
| 4 |
D.E. Shaw & Co
New York
|
+$292K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.14M |
| 2 |
PAM
Paradigm Asset Management
New York
|
-$320K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$167K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$144K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
-$89K |
LCTX Hedge Fund Activity: Q4 2013 in Review
58 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2013, worth a combined $60.9M — down 4.7% from $63.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LCTX positions and 8 closed out — a net gain of 2 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $1.12M. The largest seller was Fidelity Investments, cutting an estimated $3.14M.
- 58 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2013, up from 56 in Q3 2013.
- Funds reported $60.9M of Lineage Cell Therapeutics stock for Q4 2013, down 4.7% quarter-over-quarter.
- 10 funds opened new Lineage Cell Therapeutics positions in Q4 2013 and 8 closed out, a net change of +2 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2013 was Broadwood Capital, an estimated $1.12M added.
- The largest Lineage Cell Therapeutics seller in Q4 2013 was Fidelity Investments, an estimated $3.14M sold.
Based on aggregated 13F filings for Q4 2013.